Skip to main content

Paul Langlie Martin, MD, PhD

Professor of Pediatrics
Chief, Division of Pediatric Blood and Marrow Transplantation
Member of the Duke Cancer Institute
Campus mail: 1400 Morrene Rd, Durham, NC 27705
Phone: (919) 668-1124
Email address: paul.martin@duke.edu

For most of my career in Pediatric Hematology/Oncology I have focused on the use of stem cell transplant for the treatment of pediatric leukemias (ALL, AML, CML and JMML) and other non-malignant blood disorders, such as thalassemia, hemaphagocytic disorders, Wiskott-Aldrich, aplastic anemia, Diamond-Blackfan Anemia, as well as inherited metabolic diseases. In addition to focusing on determining the best use of stem cell transplants for these disorders, I have also been involved in clinical research investigating the prevention and treatment of transplant related morbidity, particularly veno-occlusive disease of the liver, infections and diffuse alveolar hemorrhage. As study chair for the Children's Oncology Group protocol 9904, I was involved in the development, implementation and analysis of a large, international frontline study of childhood acute lymphoblastic leukemia. Results from this study show that a significant number of children with certain favorable cytogenetic abnormalities in their leukemic cells and who have a rapid response to their initial chemotherapy can expect to have a >95% chance of cure when treated with relatively low intensity chemotherapy.

Education and Training

  • Fellow, Pediatric Hematology/Oncology, Pediatrics, Yale University, 1989 - 1992
  • Resident, Pediatrics, Yale University, 1988 - 1989
  • Intern, Pediatrics, Yale University, 1987 - 1988
  • Ph.D., Washington University in St. Louis, 1987
  • M.D., Washington University in St. Louis, 1987

Publications

Richardson, Paul G., Marcie Riches, Nancy A. Kernan, Joel A. Brochstein, Shin Mineishi, Amanda M. Termuhlen, Sally Arai, et al. “Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial.” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.

Scholars@Duke

Moriyama, Takaya, Monika L. Metzger, Gang Wu, Rina Nishii, Maoxiang Qian, Meenakshi Devidas, Wenjian Yang, et al. “Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study..” Lancet Oncol 16, no. 16 (December 2015): 1659–66. https://doi.org/10.1016/S1470-2045(15)00369-1.

Full Text

Allewelt, Heather, Paul L. Martin, Paul Szabolcs, Nelson Chao, Rebecca Buckley, and Suhag Parikh. “Hematopoietic Stem Cell Transplantation for CD40 Ligand Deficiency: Single Institution Experience..” Pediatr Blood Cancer 62, no. 12 (December 2015): 2216–22. https://doi.org/10.1002/pbc.25711.

Full Text

Mahadeo, Kris M., Priti Tewari, Suhag H. Parikh, Timothy A. Driscoll, Kristin Page, Paul L. Martin, Joanne Kurtzberg, and Vinod K. Prasad. “Durable engraftment and correction of hematological abnormalities in children with congenital amegakaryocytic thrombocytopenia following myeloablative umbilical cord blood transplantation..” Pediatr Transplant 19, no. 7 (November 2015): 753–57. https://doi.org/10.1111/petr.12577.

Full Text

Yasuda, Eriko, William Mackenzie, Kristen Ruhnke, Tsutomu Shimada, Robert W. Mason, Jozef Zustin, Paul L. Martin, et al. “Molecular Genetics and Metabolism Report Long-term follow-up of post hematopoietic stem cell transplantation for Hurler syndrome: clinical, biochemical, and pathological improvements..” Mol Genet Metab Rep 2 (March 2015): 65–76. https://doi.org/10.1016/j.ymgmr.2014.12.006.

Full Text

Richardson, Paul G., Nancy A. Kernan, Stephan A. Grupp, Paul L. Martin, Robert J. Soiffer, Richard Martin, Alison Hannah, and Kathleen F. Villa. “Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival.” In Biology of Blood and Marrow Transplantation, 21:S110–S110. Elsevier BV, 2015. https://doi.org/10.1016/j.bbmt.2014.11.138.

Full Text

Ciocci, Gil, Lauren Stafford, Timothy A. Driscoll, Paul L. Martin, and Joanne Kurtzberg. “Hyperthyroidism As a Complication Following Myloablative Therapy and Stem Cell Transplantation for Childhood Diseases.” In Biology of Blood and Marrow Transplantation, 21:S214–15. Elsevier BV, 2015. https://doi.org/10.1016/j.bbmt.2014.11.329.

Full Text

McFarren, Alicia, P Brian Smith, Kristin Page, Heather B. Allewelt, Suhag Parikh, Timothy A. Driscoll, Paul L. Martin, Joanne Kurtzberg, and Vinod K. Prasad. “Outcomes of Second Unrelated Donor Cord Blood Transplants (UCBT) Performed in Children with Graft Failure of Autologous Recovery Following the First UCBT.” In Biology of Blood and Marrow Transplantation, 21:S37–38. Elsevier BV, 2015. https://doi.org/10.1016/j.bbmt.2014.11.030.

Full Text

Satwani, P., Z. Jin, P. L. Martin, M. Bhatia, J. H. Garvin, D. George, S. Chaudhury, et al. “Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma..” In Leukemia, 29:448–55, 2015. https://doi.org/10.1038/leu.2014.194.

Full Text

Richardson, Paul G., Nancy A. Kernan, Stephan A. Grupp, Paul L. Martin, Robert J. Soiffer, Richard Martin, Alison L. Hannah, and Kathleen F. Villa. “Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival.” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.

Scholars@Duke

Pages